SAN DIEGO and CALGARY, AB, April 5, 2021 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) right this moment introduced that it’s going to host a Key Opinion Chief (KOL) webinar discussing AWARE-1 information, the immunotherapeutic results of pelareorep in breast most cancers, and its synergistic exercise with CAR T cells in stable tumors. The webinar will happen on Monday, April 12, 2021 at 2:00 pm ET.
The webinar will function shows by Key Opinion Leaders Aleix Prat, M.D., Ph.D. (Clínic Barcelona) and Richard Vile, Ph.D., (Mayo Clinic). Dr. Prat’s portion of the presentation will give attention to information from the AWARE-1 window-of-opportunity scientific trial evaluating pelareorep with and with out atezolizumab (Tecentriq®) in early-stage breast most cancers, which will probably be offered at this 12 months’s American Affiliation for Most cancers Analysis (AACR) Annual Assembly. Dr. Vile will then talk about the outcomes of a preclinical research evaluating pelareorep and chimeric antigen receptor (CAR) T cell mixture remedy in stable tumors (link to PR, link to poster).
Through the occasion, Oncolytics’ administration staff can even give a company replace and talk about the corporate’s upcoming milestones. Dr. Prat, Dr. Vile, and firm administration will probably be out there to reply questions following the formal shows.
To register for the occasion, please click on here.
In regards to the KOLs
Aleix Prat, M.D., Ph.D. is the Head of the Medical Oncology Division of the Hospital Clínic Barcelona (Spain), Affiliate Professor on the College of Barcelona, Head of the Translational Genomics and Focused Therapeutics in Strong Tumors Lab at IDIBAPS, and President of the governing board of the Spanish Breast Most cancers Cooperative Analysis Group (SOLTI), which performs scientific trials of excellence in oncology. He was additionally named a member of the Govt Board of The Breast Worldwide Group (BIG) in 2018. BIG is a world non-profit group that’s linked to greater than 3,000 hospitals and consists of greater than 10,000 specialists and greater than 56 cooperative teams from around the globe.
Over his profession, Dr. Prat obtained worldwide status as a analysis scientist within the subject of breast most cancers genomics and biomarker improvement. In 2008, he turned a postdoctoral analysis affiliate (2008-2012) on the Lineberger Complete Most cancers Middle (College of North Carolina at Chapel Hill, USA) within the Laboratory of Prof. Charles M. Perou, a world-renowned translational researcher in breast most cancers. Throughout this postdoctoral expertise, he found and characterised a brand new molecular subtype of breast most cancers, generally known as a Claudin-low (Prat et al. Breast Most cancers Analysis 2010; Citations: 1,518). As well as, he contributed to the breast most cancers portion of The Most cancers Genome Atlas (Nature 2012; Citations: 4,661), which was a landmark molecular characterization research within the subject of most cancers analysis.
Richard Vile, Ph.D. is a world-renowned scientist and member of the Oncolytics Scientific Advisory Board with in depth expertise finding out pelareorep. As a acknowledged KOL, his analysis focuses on a number of areas of immuno-oncology, together with oncolytic viruses, adoptive cell therapies (ACTs) corresponding to chimeric antigen receptor (CAR) T cells, and potential synergistic interactions between oncolytic viruses and ACTs. Along with his position as a professor on the Mayo Clinic (“Mayo”), Dr. Vile is the Director of Mayo’s Immuno-oncology and Gene and Virus Remedy packages and Co-Director of the Most cancers Immunology and Immunotherapy program. He additionally serves on the editorial board of a number of prestigious scientific journals, together with Molecular Remedy, Gene Remedy, The Journal of Gene Drugs, and OncoImmunology. Dr. Vile acquired his B.A. in Biochemistry from the College of Oxford and his Ph.D. in Viral Vectors from the College of London.
AWARE-1 is an open label window-of-opportunity research in early-stage breast most cancers enrolling 38 sufferers into 5 cohorts:
- Cohort 1 (n=10), HR+ / HER2- (pelareorep + letrozole)
- Cohort 2 (n=10), HR+ / HER2- (pelareorep + letrozole + atezolizumab)
- Cohort 3 (n=6), TNBC (pelareorep + atezolizumab)
- Cohort 4 (n=6), HR+ / HER2+ (pelareorep + trastuzumab + atezolizumab)
- Cohort 5 (n=6), HR- / HER2+ (pelareorep + trastuzumab + atezolizumab)
The research combines pelareorep, with or without atezolizumab, and the usual of care remedy based on breast most cancers subtype. Tumor tissue is collected from sufferers as a part of their preliminary breast most cancers analysis, once more on day three following preliminary therapy, and at last at three weeks following therapy, on the day of their mastectomy. Knowledge generated from this research are meant to verify that pelareorep is appearing as a novel immunotherapy, to judge potential synergy between pelareorep and checkpoint blockade, and to offer complete biomarker information by breast most cancers subtype. The first endpoint of the research is total CelTIL rating (a measurement of cellularity and tumor-infiltrating lymphocytes). Secondary endpoints for the research embrace CelTIL by breast most cancers subtype, security, and tumor and blood-based biomarkers.
For extra details about the AWARE-1 research, confer with https://clinicaltrials.gov/ct2/show/NCT04102618.
Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the therapy of stable tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an infected tumor phenotype by way of innate and adaptive immune responses to deal with quite a lot of cancers and has been demonstrated to have the ability to escape neutralizing antibodies present in sufferers.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology firm growing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an infected tumor phenotype — turning “chilly” tumors “scorching” — by way of innate and adaptive immune responses to deal with quite a lot of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may be synergistic with different authorized immuno-oncology brokers. Oncolytics is at the moment conducting and planning extra research of pelareorep together with checkpoint inhibitors and focused therapies in stable and hematological malignancies, because it prepares for a section 3 registration research in metastatic breast most cancers. For additional info, please go to: www.oncolyticsbiotech.com.
This press launch incorporates forward-looking statements, inside the which means of Part 21E of the Securities Alternate Act of 1934, as amended and forward-looking info beneath relevant Canadian securities legal guidelines (such forward-looking statements and forward-looking info are collectively referred to herein as “forward-looking statements”). Ahead-looking statements contained on this press launch embrace statements relating to Oncolytics’ perception as to the potential and advantages of pelareorep as a most cancers therapeutic; Oncolytics’ expectations as to the aim, design, outcomes and advantages of its present or pending scientific trials involving pelareorep; and different statements associated to anticipated developments in Oncolytics’ enterprise and applied sciences. In any forward-looking assertion through which Oncolytics expresses an expectation or perception as to future outcomes, such expectations or beliefs are expressed in good religion and are believed to have an affordable foundation, however there may be no assurance that the assertion or expectation or perception will probably be achieved. Such forward-looking statements contain recognized and unknown dangers and uncertainties, which may trigger Oncolytics’ precise outcomes to vary materially from these within the forward-looking statements. Such dangers and uncertainties embrace, amongst others, the supply of funds and sources to pursue analysis and improvement tasks, the efficacy of pelareorep as a most cancers therapy, the success and well timed completion of scientific research and trials, Oncolytics’ capability to efficiently commercialize pelareorep, uncertainties associated to the analysis and improvement of prescribed drugs, uncertainties associated to the regulatory course of and basic adjustments to the financial atmosphere. Particularly, we could also be impacted by enterprise interruptions ensuing from COVID-19 coronavirus, together with working, manufacturing provide chain, scientific trial and venture improvement delays and disruptions, labour shortages, journey and delivery disruption, and shutdowns (together with because of authorities regulation and prevention measures). It’s unknown whether or not and the way Oncolytics could also be affected if the COVID-19 pandemic persists for an prolonged time period. We could incur bills or delays regarding such occasions exterior of our management, which may have a fabric hostile influence on our enterprise, working outcomes and monetary situation. Buyers ought to seek the advice of Oncolytics’ quarterly and annual filings with the Canadian and U.S. securities commissions for extra info on dangers and uncertainties regarding the forward-looking statements. Buyers are cautioned in opposition to putting undue reliance on forward-looking statements. The Firm doesn’t undertake any obligation to replace these forward-looking statements, besides as required by relevant legal guidelines.
SOURCE Oncolytics Biotech® Inc.